Dr Charlene McShane
While we don’t know what causes most cases of myeloma, a type of blood cancer, we know most patients had a rare underlying condition called monoclonal gammopathy of undetermined significance (MGUS). But the majority of people with MGUS don’t go on to develop myeloma.
At the Queen’s University Belfast, Dr Charlene McShane is studying MGUS to find out more about the factors that could play a role in the progression of this condition to cancer. By combining anonymised patient, clinical and laboratory data, Dr McShane hopes to be able to investigate patient outcomes and to develop tools that can help doctors tell how likely it is that a person with MGUS will develop myeloma.
Using these tools, Dr McShane will also compare follow-up strategies – those currently used versus new strategies based on a person’s risk of progressing to cancer – and evaluate their cost-effectiveness. In doing to, Dr McShane’s research could have an impact on decision making in the clinic and potentially reduce the burden of disease on patients.